Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Current vascular targeting strategies pursue two main goals: anti-angiogenesis agents aim to halt sprouting and the formation of new blood vessels, while vascular disrupting agents along with coaguligands seek to compromise blood circulation in the vessels. The ultimate goal of such therapies is to deprive tumor cells out of oxygen and nutrients long enough to succumb cancer cells to death. Most of vascular targeting agents presented promising therapeutic potential, but the final goal which is cure is rarely achieved. Nevertheless, in both preclinical and clinical settings, tumors tend to grow back, featuring a highly invasive, metastatic, and extremely resistant form. This review highlights the critical significance of tumor rim cells as the main factor, determining therapy success with vascular targeting agents. We present an overview of different single and combination treatments with vascular targeting agents that enable efficient targeting of tumor rim cells and long-lasting tumor cure. Understanding the nature of tumor rim cells, how they establish, how they manage to survive of vascular targeting agents, and how they contribute in tumor refractoriness, may open new avenues to the development of beneficial strategies, capable to eliminate residual rim cells, and enable tumor ablation once and forever.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To this end, most primary strategies are directed at inhibiting tumor angiogenesis by blocking either growth factors or factors involved in endothelial cell migration, survival, and proliferation (Fig. 2a) [50] (see for review [3, 51]).”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [51]
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Photodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
The role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Research works printed but not linked: 19
- Tandle A, 2004, J Transl Med, 2, 1
- Ran S, 1998, Cancer Res, 58, 4646
- Hu P, 2003, Cancer Res, 63, 5046
- Seon BK, 1997, Clin Cancer Res, 3, 1031
- Matsuno F, 1999, Clin Cancer Res, 5, 371
- Halin C, 2003, Cancer Res, 63, 3202
- Ciardiello F, 2003, Clin Cancer Res, 9, 1546
- Pedley RB, 1996, Cancer Res, 56, 3293
- Pedley RB, 2001, Cancer Res, 61, 4716
- Green C, 2005, Proc Amer Assoc Cancer Res, 46, 2990
- Green C, 2006, Proc Amer Assoc Cancer Res, 47, 514
- Kanwar JR, 2001, Cancer Res, 61, 1948
- Nilsson F, 2001, Cancer Res, 61, 711
- Liu C, 2002, Cancer Res, 62, 5470
- Arora N, 1999, Cancer Res, 59, 183
- Tijink BM, 2006, J Nucl Med, 47, 1127
- Scappaticci FA, 2003, Anticancer Res, 23, 1165
- Hou J, 2004, Cell Mol Immunol, 1, 161
- Patyar S, 2010, J Biomed Sci, 17, 1
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“2a ) [50] (see for review [3, 51] ).”
Self-citationAdvances of medical nanorobots for future cancer treatments
Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01463-z · Cited by 238
Al-Abd, A. M., Alamoudi, A. J., Abdel-Naim, A. B., Neamatallah, T. A., & Ashour, O. M. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.06.006 · Cited by 198
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
Tumor target amplification: Implications for nano drug delivery systems
Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.020 · Cited by 145
Self-citation
Metadata
- Authors
- Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N.
- Affiliations
- Tabriz University of Medical Sciences (IR)
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
- Corresponding author
- Zarghami, Nosratollah
- Venue
- Tumor Biology
- Publisher
- SAGE Publications
- Published
- 2017-03
- Volume
- 39
- Issue
- 3
- Pages
- 101042831769100
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2599903719
- Cited by
- 41
- References
- 115
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 2 · 2020: 6 · 2019: 1 · 2018: 5 · 2017: 4
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Tumor Biology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Tabriz
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- vascular targeting agents, vascular disrupting agents, tumor resistance, tumor ablation, tumor recurrence, combination therapy, tumor hypoxia
- MeSH terms
- Blood Vessels, Humans, Neoplasms, Neovascularization, Pathologic, Remission Induction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. https://app.cochat.ai/papers/10.1177/1010428317691001
- The paper
- Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017). Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. Tumor Biology. https://doi.org/10.1177/1010428317691001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.